BRONCHIAL ASTHMA IS A DISEASE THAT LEADS TO INTRAUTERINE HYPOXIA

The incidence of bronchial asthma (BA) in the world is from 4 to 10% of the population [6, 14]; in the Russian Federation, the prevalence among adults it ranges from 2.2 to 5–7% [15], in the pediatric population this figure is about 10% [9]. In pregnant women, bronchial asthma is the most common disease of the pulmonary system, the frequency of diagnosis of which in the world ranges from 1 to 4% [3], in Russia – from 0.4 to 1% [8]. In recent years, standard international diagnostic criteria and methods of pharmacotherapy have been developed, which can significantly increase the effectiveness of treatment of patients with asthma and improve their quality of life (Global Initiative for the Prevention and Treatment of Asthma (GINA), 2014) [14]. However, modern pharmacotherapy and monitoring of asthma in pregnant women are more complex tasks, since they are aimed not only at maintaining the health of the mother, but also at preventing the adverse effects complications of the disease and side effects of treatment on the fetus.